GeoVax

GeoVax Labs, Inc., of Smyrna, Georgia, describes itself in its November 2026 registration statement as a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and solid tumours. Its near-term priority is a Modified Vaccinia Ankara vaccine for mpox and smallpox. Its lead oncology programme is Gedeptin, a gene-directed enzyme prodrug therapy licensed from PNP Therapeutics in September 2021: a replication-deficient adenovirus carries a non-human gene into tumour cells, and the enzyme it makes converts the prodrug fludarabine phosphate into an active anti-tumour compound inside the tumour. The company reports a completed multi-site phase 1b/2a trial (PNP-002, NCT03754933) of repeat cycles in advanced head and neck squamous cell carcinoma, an FDA orphan drug designation for intratumoral treatment of accessible oral and pharyngeal cancers, and plans a phase 2 trial with a checkpoint inhibitor before curative surgery in the second half of 2027.